However, the clinical use of pan-HDAC inhibitors in cancer patients has been, in part, associated with several challenges and side effects in some patients [312,313,314] that might be due to their broad activity across numerous HDAC isoforms and, thus, the concurrent inactivation of multiple HDAC family members, including their individual signalling. Here, HDAC9 is linked to cancer.